SEMA3B and osteoporosis: It inhibits miR-21 and semaphorin 3B (Sema3B) via Wnt/β-catenin signaling, impairing MSC osteogenic differentiation in estrogen-deficient osteoporosis, leading to reduced bone mineral density and trabecular abnormalities (76).